Information Provided By:
Fly News Breaks for January 8, 2020
Jan 8, 2020 | 07:47 EDT
Credit Suisse analyst Matt Miksic says he has updated his differentiated "two-stage" valuation model for Edwards Lifesciences, which supports potential upside to EW over the next 12 months to $295-$300, boosting his confidence in his $275 price target for the stock. The analyst reiterates an Outperform rating on the shares as he expects Edwards Lifesciences to continue to substantially outperform his universe and the market in 2020.